Table 2 Treatment in patients with T2DM
|  | T2DM (CAD −) (n = 178) | T2DM (CAD +) (n = 104) | P value |
|---|---|---|---|
Diabetic treatment | |||
 Biguanides, n (%) | 59 (33.1%) | 43 (41.4%) | 0.167 |
 Sulfonylureas, n (%) | 31 (17.4%) | 18 (17.3%) | 0.982 |
 a-Glucosidase inhibitor, n (%) | 48 (27%) | 31 (29.8%) | 0.608 |
 GLP-1/DPP-4 inhibitor, n (%) | 9 (5%) | 5 (4.8%) | 0.926 |
 Insulin, n (%) | 46 (25.8%) | 38 (36.5%) | 0.058 |
 Diet controlled | 60 (33.7%) | 22 (21.2%) | 0.025 |
CAD treatment | |||
 Drugs | |||
  Aspirin, n (%) | – | 83 (79.8%) | – |
  Clopidogrel, n (%) | – | 73 (70.2%) | – |
  Warfarin, n (%) | – | 3 (2.9%) | – |
  Statins, n (%) | – | 89 (85.6%) | – |
  Beta blockers, n (%) | – | 44 (42.3%) | – |
  ACEI, ARB, n (%) | – | 40 (38.5%) | – |
  Nitrate, n (%) | – | 8 (7.7%) | – |
  Trimetazidine hydrochloride, n (%) | – | 14 (13.5%) | – |
  Calcium antagonists, n (%) | – | 26 (25%) | – |
 PCI | – | 64 (61.5%) | – |
 CABG | – | 3 (2.9%) | – |